marked.bio

Company

Radiopharm Theranostics

2 active trials that select patients by a biomarker on marked.bio, across 2 biomarkers.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Trials

2 of 2 trials shown

  1. HEAT Trial (HER2 Antibody Therapy With Lutetium-177)

    Recruiting Early Phase 1 Radiopharm Theranostics Started 2025Primary completion 2027-12 NCT06824155

    177Lu-RAD202

    Participants with histologically or cytologically confirmed, HER2 positive or HER2-low, advanced solid tumours that are relapsed/refractory, locally advanced not amenable to cu…

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)HER2 Gene Mutation, Advanced Solid Tumors

  2. 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors

    Recruiting Early Phase 1 Radiopharm Theranostics Started 2024Primary completion 2027-12 NCT06305962

    177Lu-RAD204

    …us melanoma, HNSCC, endometrial cancer or any cancer that is known to be MMR deficient or MSI high with documented disease progression during or after their most recent line of anticancer …

    MSI-H / dMMRPDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer